| 000 | 01692 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515191622.0 | ||
| 264 | 0 | _c20100105 | |
| 008 | 201001s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2009-06-225474 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLi, Bohua | |
| 245 | 0 | 0 |
_aCharacterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. _h[electronic resource] |
| 260 |
_bBlood _cDec 2009 |
||
| 300 |
_a5007-15 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xchemistry |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 | _aAntibody Affinity |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aComplementarity Determining Regions _xgenetics |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 | _aPoint Mutation |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aZhao, Lei | |
| 700 | 1 | _aGuo, Huaizu | |
| 700 | 1 | _aWang, Chong | |
| 700 | 1 | _aZhang, Xunming | |
| 700 | 1 | _aWu, Lan | |
| 700 | 1 | _aChen, Lin | |
| 700 | 1 | _aTong, Qing | |
| 700 | 1 | _aQian, Weizhu | |
| 700 | 1 | _aWang, Hao | |
| 700 | 1 | _aGuo, Yajun | |
| 773 | 0 |
_tBlood _gvol. 114 _gno. 24 _gp. 5007-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2009-06-225474 _zAvailable from publisher's website |
| 999 |
_c19222049 _d19222049 |
||